MSH|^~\&#|LOI_NG_PRU_PROFILE^2.16.840.1.113883.9.87^ISO|LOI_NG_PRU_PROFILE^2.16.840.1.113883.9.87^ISO|LOI_NG_PRU_PROFILE^2.16.840.1.113883.9.87^ISO|LOI_NG_PRU_PROFILE^2.16.840.1.113883.9.87^ISO|20170926200714.2726+0530||ORU^R01^ORU_R01|MessageID123|P|2.5.1|||AL|AL|||||PHLabReport-Ack^LOI_NG_PRU_PROFILE^2.16.840.1.113883.9.11^ISO|SFT|HC|HC|HC|HC|||PID|1||1^2^ISO^LOI_NG_PRU_PROFILE&2.16.840.1.113883.9.87&ISO^ANC||Decouza^Harry^M||20170101000000+0530|ORC|RE|ORD170^NDA^2.16.840.1.113883.9.87^ISO|2^8^2.16.840.1.113883.9.87^ISO|||F||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^|||||||||HC|HC|^BPN^BP^BP^^^|OBR|1|ORD170^NDA^2.16.840.1.113883.9.87^ISO|2^8^2.16.840.1.113883.9.87^ISO|31019-3^10-Hydroxycarbazepine [Mass/?volume] in Serum or Plasma^LN|||20170101000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170108000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|2|ORD170^NDA^2.16.840.1.113883.9.87^ISO|4^8^2.16.840.1.113883.9.87^ISO|31019-3^10-Hydroxycarbazepine [Mass/?volume] in Serum or Plasma^LN|||20170101000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170108000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|SPM|1|HC^HC&HC&2.16.840.1.113883.9.87&ISO||UR^Urine^HL70487|||||||||||||20170101000000+0530|20170302000000+0530|